Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R S Herbst

Showing results (1-10 of 52) with videos related to

Pageof 6
Sort By:
British Journal of Cancer|June 2, 2005
Role of novel targeted therapies in the clinicR S Herbst
Seminars in Oncology|December 10, 1999
Gemcitabine and vinorelbine combinations in the treatment of non-small cell lung cancerR S Herbst, R Lilenbaum
Clinical Lung Cancer|January 21, 2004
Vinorelbine and gemcitabine combinations in advanced non small-cell lung cancerR C Lilenbaum, R S Herbst
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 13, 2001
Angiogenesis and lung cancer: potential for therapyR S Herbst, I J Fidler
Journal of Cellular Biochemistry|January 1, 1990
Cis effect of the type 5 adenovirus E1A gene enhancer element on cellular transformationR S Herbst, M Pelletier, L E Babiss
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 14, 2001
Thalidomide, cyclooxygenase-2, and angiogenesis: potential for therapyA Onn, J E Tseng, R S Herbst
Cancer Chemotherapy and Pharmacology|April 29, 1998
Paclitaxel/carboplatin administration along with antiangiogenic therapy in non-small-cell lung and breast carcinoma modelsR S Herbst, H Takeuchi, B A Teicher
Current Opinion in Oncology|October 24, 2001
Epidermal growth factor receptor biology (IMC-C225)E S Kim, F R Khuri, R S Herbst
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 4, 2001
Emerging therapies in non-small-cell lung cancerF R Khuri, R S Herbst, F V Fossella
Expert Opinion on Biological Therapy|December 1, 2001
IMC-C225, an anti-epidermal growth factor receptor monoclonal antibody, for treatment of head and neck cancerR S Herbst, E S Kim, P M Harari
Pageof 6

Showing results (1-10 of 52) with videos related to

Sort By:
Pageof 6
British Journal of Cancer|June 2, 2005
Role of novel targeted therapies in the clinicR S Herbst
Seminars in Oncology|December 10, 1999
Gemcitabine and vinorelbine combinations in the treatment of non-small cell lung cancerR S Herbst, R Lilenbaum
Clinical Lung Cancer|January 21, 2004
Vinorelbine and gemcitabine combinations in advanced non small-cell lung cancerR C Lilenbaum, R S Herbst
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 13, 2001
Angiogenesis and lung cancer: potential for therapyR S Herbst, I J Fidler
Journal of Cellular Biochemistry|January 1, 1990
Cis effect of the type 5 adenovirus E1A gene enhancer element on cellular transformationR S Herbst, M Pelletier, L E Babiss
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 14, 2001
Thalidomide, cyclooxygenase-2, and angiogenesis: potential for therapyA Onn, J E Tseng, R S Herbst
Cancer Chemotherapy and Pharmacology|April 29, 1998
Paclitaxel/carboplatin administration along with antiangiogenic therapy in non-small-cell lung and breast carcinoma modelsR S Herbst, H Takeuchi, B A Teicher
Current Opinion in Oncology|October 24, 2001
Epidermal growth factor receptor biology (IMC-C225)E S Kim, F R Khuri, R S Herbst
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 4, 2001
Emerging therapies in non-small-cell lung cancerF R Khuri, R S Herbst, F V Fossella
Expert Opinion on Biological Therapy|December 1, 2001
IMC-C225, an anti-epidermal growth factor receptor monoclonal antibody, for treatment of head and neck cancerR S Herbst, E S Kim, P M Harari
Pageof 6